Yonhap Infomax NewsMay 9, 2025
SK Biopharm reports Q1 operating profit of 25.7 billion won, up 149% year-on-year, driven by U.S. sales growth of epilepsy drug Xcopri, despite lower-than-expected results and temporary factors affecting overall sales.
#YonhapInfomax #SKBiopharm #Q1Earnings #Xcopri #OperatingProfit #EpilepsyTreatment #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=62465
SK Biopharm Q1 Operating Profit Up 149% to 25.7 Billion Won - 'Xcopri Sales on Track'

SK Biopharm reports Q1 operating profit of 25.7 billion won, up 149% year-on-year, driven by U.S. sales growth of epilepsy drug Xcopri, despite lower-than-expected results and temporary factors affecting overall sales.

Yonhap Infomax
Yonhap Infomax NewsMay 9, 2025
SK Biopharm reports Q1 operating profit of 25.7 billion won, up 149% year-on-year but below market expectations, with sales rising 26.7% to 144.4 billion won
#YonhapInfomax #SKBiopharm #Q1Earnings #OperatingProfit #MarketExpectations #PharmaceuticalIndustry #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=62439
SK Biopharm Q1 Operating Profit Up 149% to 25.7 Billion Won - Below Expectations

SK Biopharm reports Q1 operating profit of 25.7 billion won, up 149% year-on-year but below market expectations, with sales rising 26.7% to 144.4 billion won

Yonhap Infomax
Yonhap Infomax NewsMay 8, 2025
SK Biopharm forecasts 230% increase in Q1 operating profit, driven by strong Xcopri sales despite absence of milestone payments, as company navigates potential U.S. tariff challenges
#YonhapInfomax #SKBiopharm #Xcopri #OperatingProfit #Q1Earnings #PharmaceuticalSales #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=62393
SK Biopharm Forecasts 230% Increase in Q1 Operating Profit, Thanks to Xcopri

SK Biopharm forecasts 230% increase in Q1 operating profit, driven by strong Xcopri sales despite absence of milestone payments, as company navigates potential U.S. tariff challenges

Yonhap Infomax